期刊文献+

7例凝血因子Ⅻ缺乏症患者临床报道和文献复习 被引量:2

Coagulation factor Ⅻ deficiency:Clinical report of 7 patients and literature review
下载PDF
导出
摘要 目的回顾性分析2016年2月~2020年1月就诊于本院的凝血因子Ⅻ缺乏症7例病例患者临床表现、实验室特征,以提高对此类疾病诊治方法的认识。方法对7例病例凝血因子Ⅻ缺乏患者的临床资料进行分析,并复习相关文献。结果 7例患者均以APTT明显延长为主要表现,无出血、血栓表现,有1例有阳性家族史,有1例为肿瘤继发的获得性凝血因子Ⅻ缺乏症。结论临床工作中APTT延长但无出血表现患者需全面筛查相关内外源凝血因子和获得性因素非常必要,以避免漏诊,误诊以及过度治疗。 Objective To retrospectively analyze the clinical manifestations and laboratory characteristics of 7 patients with coagulation factorⅫdeficiency in our hospital from February 2016 to January 2020 in order to improve the understanding of diagnosis and treatment for the diseases.Methods The clinical data of 7 patients with coagulation factorⅫdeficiency were analyzed,and related literatures were reviewed.Results All the 7 patients showed significantly prolonged APTT without bleeding or thrombosis.Among them,1 had a positive family history,and 1 acquired coagulation factorⅫdeficiency secondary to the tumor.Conclusion It is very necessary to comprehensively screen related internal and external coagulation factors and acquired factors in patients with prolonged APTT but no bleeding,so as to avoid missed diagnosis,misdiagnosis and over treatment.
作者 古再丽努尔·吾甫尔 陶玲 富玲 毛敏 GH Zailinur Wufuer;TAO Ling;FU Ling;MAO Min(Department of Hematology,People's Hospital of Xinjiang Uygur Autonomous Region,Urumqi 830000,China)
出处 《中国输血杂志》 CAS 2021年第7期779-781,共3页 Chinese Journal of Blood Transfusion
关键词 凝血因子Ⅻ缺乏症 病因 临床特点 实验室特征 治疗 coagulation factorⅫdeficiency pathogeny clinical characteristics laboratory characteristics treatment
  • 相关文献

参考文献1

二级参考文献17

  • 1Dimopoulos MA, Kyle RA, Anagnostopoulos A, et al. Diagnosis andmanagement of Waldenstrom' s macroglobulinemia [J]. J Clin Onco1,2005,23 ( 7 ) : 1564-1577.
  • 2Owen RG, Treon SP, A1-Katib A, et al. Clinieopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia [J]. Semin Oncol, 2003,30 (2) :110-115.
  • 3Sahota SS, Forconi F, Ottensmeier CH, Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events [ J ]. Blood, 2002,100(4) :1505-1507.
  • 4Braggio E, Keats JJ, Leleu X, et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom' s macroglobulinemia [ J ]. Cancer Res, 2009,69 ( 8 ) :3579-3588.
  • 5Treon SP, Xu L, Yang G, et al. Whole genome sequencing reveals a widely expressed mutation (MYD88 L265P) with oncogenic activity in Waldenstrom's macroglobulinemia [ J]. Blood, 2011, 118(21) :300.
  • 6Kyle RA, Themean TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance [J ]. Blood, 2003,102 ( 10 ) : 3759 -3764.
  • 7Kristinsson SY, BjSrkholm M, Goldin LR, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients:a population-based study in Sweden [J]. Blood,2008, 112 ( 8 ) :3052-3056.
  • 8Kristinsson SY, Goldin LR, Turesson I, et al. Familial aggregation of lymphoplasmacytic lymphoma/Waldenstrm macroglobulinemia with solid tumors and myeloid malignancies [ J ]. Acta Haematol, 2012,127(3) : 173-177.
  • 9Leleu X, Xie W, Bagshaw M, et al. The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia [J]. Clin Cancer Res, 2011, 17 (9) :3013-3018.
  • 10Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia [ J]. Blood, 2009,113 (18) :4163-4170.

共引文献2

同被引文献16

引证文献2

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部